ATL relies on natural uptake to deliver ATL1102 to immune cells...

ATL relies on natural uptake to deliver ATL1102 to immune cells that play a role in the inflammatory muscle damage and is used at a low 25mg/week sc doses (0.4mg/kg) i.e 100x lower dose

. Keeping muscle intact with ATL1102 may enable better outcome with dystrophin producing drugs and this is to be tested for in animal studies.
————
Itsa: : Does not see PGN-ED051 (PepGen)and Sareptas SRP 5051 as a threat to Atl1102 for DMD.and am confident Atl1102 will capture 100% of the DMD market.

If the combination study in animals ( delay in getting the right type of mice ) proves efficacy “Game Over”
Sarepta will want part of the action $$$

This is why Itsa is confident that $$$ 70/100 million will not be a problem come futility…

I keep on saying imo this is a $5 minimum stock
Just on Non Ambulant boys $4 billion
Ambulant boys $6 billion ( market by 2030)
like Mac9 says… earnings x10 ( conservative)
Mind blowing… and people you can pick up shares @13c…crazy

Add to this all Anp has to achieve is the same endpoints as the last DMD trial in Australia.
Boom!!! Commercialisation $$